BioAge Labs, Inc.
harnessing the biology of human aging to develop new therapies for metabolic diseases
About BioAge Labs, Inc.
harnessing the biology of human aging to develop new therapies for metabolic diseases
Products
potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases
long-acting injectable and oral small molecule APJ agonists for obesity
human-first platform analyzing proprietary longitudinal human samples and health records spanning 45+ years to identify molecular mediators of aging
Security and compliance
No security details published yet
BioAge Labs, Inc. hasn't published certifications or security practices that we could find. Ask their team for audit reports.
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim BioAge Labs, Inc.